APA (7th ed.) Citation

Damotte, D., Warren, S., Arrondeau, J., Boudou-Rouquette, P., Mansuet-Lupo, A., Biton, J., . . . Ren, X. (2019). The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. Journal of Translational Medicine, 17(1), N.PAG. https://doi.org/10.1186/s12967-019-2100-3

Chicago Style (17th ed.) Citation

Damotte, Diane, et al. "The Tumor Inflammation Signature (TIS) Is Associated with Anti-PD-1 Treatment Benefit in the CERTIM Pan-cancer Cohort." Journal of Translational Medicine 17, no. 1 (2019): N.PAG. https://doi.org/10.1186/s12967-019-2100-3.

MLA (9th ed.) Citation

Damotte, Diane, et al. "The Tumor Inflammation Signature (TIS) Is Associated with Anti-PD-1 Treatment Benefit in the CERTIM Pan-cancer Cohort." Journal of Translational Medicine, vol. 17, no. 1, 2019, p. N.PAG, https://doi.org/10.1186/s12967-019-2100-3.